Nasdaq ETFs

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $2.7 billion dollar inflow -- that's a 2.6% increase week over week in outsta

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $1.7 billion dollar inflow -- that's a 0.6% increase week over w

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total International Stock ETF (Symbol: VXUS) where we have detected an approximate $946.4 million dollar inflow -- that's a 1.8% increase w

Amgen Inc (Symbol: AMGN) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a staggering $20.22B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.49% yield, according to the most recent Dividend Channel ''DividendRa

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel

In recent trading, shares of CubeSmart (Symbol: CUBE) have crossed above the average analyst 12-month target price of $47.88, changing hands for $48.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation,

To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention —

In recent trading, shares of Gilead Sciences Inc (Symbol: GILD) have crossed above the average analyst 12-month target price of $86.12, changing hands for $86.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on

In recent trading, shares of Booking Holdings Inc (Symbol: BKNG) have crossed above the average analyst 12-month target price of $2464.57, changing hands for $2469.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrad

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel

The biotech industry has stood out in recent months, with Immunocore Holdings PLC (NASDAQ: IMCR) among the group’s top price performers. The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharm

VanEck CEO Jan van Eck told attendees at Exchange: An ETF Experience on Monday that China has several factors favoring a recovery if it continues its pro-growth policies. “We think there’s a tailwind to what’s going on in China,” van Eck added. “It’s got all the tailwinds for cyclical recovery.” The VanEck CEO explained that the [...] Read more at ETFtrends.com.

An unexpectedly strong jobs report has put a pause on the market’s forward movement as investors remain focused on a possible Fed response to a resilient jobs market in the coming months. Uncertainty and rising rates are anticipated to weigh heavily on U.S. markets this year and for advisors and investors looking for income opportunities [...] Read more at ETFtrends.com.

Advisors and issuers alike are celebrating the recent 30th birthday of the SPDR S&P 500 ETF (SPY) this week at Exchange: An ETF Experience. The launch of SPY in January 1993 propelled the ETF industry’s growth globally. Since its inception, SPY has had $110 trillion in total trading volume; trading more than its seven top index constituents [...] Read more at ETFtrends.com.

The last year’s debate may have been whether inflation was sticky or not, but really, it’s the debate itself that seems to be the stickiest. It’s a top concern for advisors and their clients and was the subject of the How to Tackle Inflation panel at Exchange ETFs in Miami on Monday, hosted by ETF [...] Read more at ETFtrends.com.

Corey Hoffstein’s Flirting With Models kicked off a new season at Exchange with a live recording of Hoffstein’s deep-diving interview with Mutiny’s Jason Buck, who he introduced as “the world’s most interesting man.” Buck’s company, Mutiny, is an unusual investment firm designed around ‘anti-fragility’ or ‘crisis alpha’ that is intended to achieve large asymmetric gains [...] Read more at ETFtrends.com.